Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The extension of the bridge program through 2027 eases uncertainty around reimbursement for weight-loss drugs and blunts any near-term impact on demand, but an indefinite delay clouds long-term visibility on permanent integration into Medicare prescription drug plans, analysts said
The most popular GLP-1s ( Ozempic , Wegovy , Mounjaro , Zepbound ) are administered as once-weekly injections
Originally isolated from human gastric juice, this 15-amino acid compound has been studied in preclinical animal models across multiple physiological systems.*1,9,10
Our services are overseen by certified physicians, ensuring your comfort, safety, and optimal results tailored to your unique situation
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
US$ 20.41
US$ 28.92
US$ 21.12
